Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team

Susan A Fiscus; Michael D Hughes; Janet L Lathey; Timothy Pi; J Brooks Jackson; Suraiya Rasheed; Tarek Elbeik; Richard Reichman; Anthony Japour; Roy Byington; Walter  Scott; Brigitte P Griffith; David A Katzenstein; Scott M Hammer

doi:10.1086/514248

Back

Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team

Journal article

Open access

Peer reviewed

Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team

Susan A Fiscus, Michael D Hughes, Janet L Lathey, Timothy Pi, J Brooks Jackson, Suraiya Rasheed, Tarek Elbeik, Richard Reichman, Anthony Japour, Roy Byington, …

The Journal of infectious diseases, Vol.177(3), pp.625-633

03/1998

DOI: 10.1086/514248

PMID: 9498441

Files and links (1)

url

https://doi.org/10.1086/514248View

Published (Version of record) Open Access

Abstract

The associations of CD4 cell count, plasma human immunodeficiency virus (HIV) type 1 RNA, infectious HIV titer in peripheral blood mononuclear cells, immune complex-disrupted (ICD) p24 antigen, and MT-2 assays with measures of disease progression after drug treatment were assessed in a subset of patients enrolled in AIDS Clinical Trials Group Study 175. Baseline plasma RNA levels and changes in RNA values at weeks 8 or 56 were more important predictors of disease progression than were baseline or changes in CD4 cell counts. Each 10-fold lower HIV RNA concentration at baseline and each 10-fold decrease in HIV RNA between baseline and week 8 was associated with increases of 49-61 CD4 cells/mm3 at weeks 56 and 104. In multivariate analyses, neither baseline values nor changes in infectious HIV titer nor ICD p24 antigen concentrations were associated with long-term changes in CD4 cell count. Plasma HIV-1 RNA appears to be the best predictor of long-term CD4 cell count responses and disease progression.

Biomarkers

HIV-1

Didanosine - therapeutic use

Multivariate Analysis

Prognosis

HIV Infections - virology

Humans

RNA, Viral - blood

CD4 Lymphocyte Count

Leukocytes, Mononuclear - virology

Disease Progression

HIV Infections - immunology

Adult

Anti-HIV Agents - therapeutic use

HIV Infections - drug therapy

Zidovudine - therapeutic use

Dideoxynucleosides - therapeutic use

Reverse Transcriptase Inhibitors - therapeutic use

HIV Core Protein p24 - blood

Zalcitabine - therapeutic use

Details

Title: Subtitle: Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team
Creators: Susan A Fiscus - Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, 27599-7140, USA. sfiscus@email.unc.edu
Michael D Hughes
Janet L Lathey
Timothy Pi
J Brooks Jackson
Suraiya Rasheed
Tarek Elbeik
Richard Reichman
Anthony Japour
Roy Byington
Walter Scott
Brigitte P Griffith
David A Katzenstein
Scott M Hammer
Resource Type: Journal article
Publication Details: The Journal of infectious diseases, Vol.177(3), pp.625-633
Publisher: United States
DOI: 10.1086/514248
PMID: 9498441
ISSN: 0022-1899
eISSN: 1537-6613
Grant note: AI-38858 / NIAID NIH HHS AI-27670 / NIAID NIH HHS AI-36214 / NIAID NIH HHS
Language: English
Date published: 03/1998
Academic Unit: Pathology; VPMA - Administration
Record Identifier: 9984047685102771

Metrics

12 Record Views

22 Times Cited - Web of Science